Repligen (NASDAQ:RGEN) Receives Outperform Rating from Royal Bank of Canada
Royal Bank of Canada restated their outperform rating on shares of Repligen (NASDAQ:RGEN – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $190.00 price target on the biotechnology company’s stock. RGEN has been the topic of several other research reports. Guggenheim initiated coverage on Repligen […]
More Stories
Neurogene (NASDAQ:NGNE) Price Target Raised to $60.00
Neurogene (NASDAQ:NGNE – Free Report) had its price objective upped by Stifel Nicolaus from $44.00 to $60.00 in a research...
Tokio Marine Asset Management Co. Ltd. Has $2.52 Million Stock Position in Intercontinental Exchange, Inc. (NYSE:ICE)
Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Intercontinental Exchange, Inc. (NYSE:ICE – Free Report) by...
Valley Wealth Managers Inc. Purchases 8,833 Shares of Tapestry, Inc. (NYSE:TPR)
Valley Wealth Managers Inc. lifted its position in Tapestry, Inc. (NYSE:TPR – Free Report) by 2.1% during the 3rd quarter,...
Archer Investment Corp Lowers Stock Holdings in Tesla, Inc. (NASDAQ:TSLA)
Archer Investment Corp decreased its position in shares of Tesla, Inc. (NASDAQ:TSLA – Free Report) by 7.3% during the third...
WW International (NASDAQ:WW) Upgraded at StockNews.com
StockNews.com upgraded shares of WW International (NASDAQ:WW – Free Report) from a sell rating to a hold rating in a...
Applied Materials (NASDAQ:AMAT) Shares Gap Down Following Analyst Downgrade
Applied Materials, Inc. (NASDAQ:AMAT – Get Free Report)’s share price gapped down prior to trading on Friday after Bank of...